FDA PMA FDA Class 3 Approved 🇺🇸 United States

Coronary Drug-Eluting Stent

PMA: P030025 · Supplement: S028 · Decision Sep 24, 2008
Classifications
1
FEI Numbers
32
Registration Numbers
32

Basic Information

Device Name
Coronary Drug-Eluting Stent
Trade Name
TAXUS EXPRESS2 PACLITAXEL-ELUTING CORONARY STENT SYSTEM (MONORAIL AND OVER -THE-WIRE)
PMA Number
P030025
Supplement Number
S028
Device Class
FDA Class 3
Product Code
NIQ
Generic Name
Coronary drug-eluting stent
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
Approved
Decision Code
APPR
Decision Date
September 24, 2008
Date Received
March 13, 2006
Supplement Type
Panel Track
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N
Docket Number
08M-0547

Advisory Committee Statement

APPROVAL FOR THE TAXUS EXPRESS2 PACLITAXEL-ELUTING CORONARY STENT SYSTEM ¿ IN-STENT RESTENOSIS (ISR) INDICATION. THE DEVICE IS INDICATED FOR IMPROVING LUMINAL DIAMETER FOR THE TREATMENT OF DE NOVO LESIONS IN NATIVE CORONARY ARTERIES >=2.25 TO <=4.00 MM IN DIAMETER IN LESIONS <=28 MM IN LENGTH, AND WITHIN BARE METAL STENT RESTENOTIC LESIONS >=2.25 TO <=3.75 MM IN DIAMETER AND <=28 MM IN LENGTH.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
NIQ Coronary Drug-Eluting Stent